CMS includes Cologuard in updated Medicare Advantage Star Ratings

 

 

MADISON, Wis., April 4, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage plans now can help increase their Star Ratings when their beneficiaries complete Cologuard, Exact Sciences' non-invasive colon cancer screening test. 
 
Read More

Exact Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test

AACR abstract highlights methylation markers capable of detecting all types of lung cancer with more than 90% sensitivity and specificity

MADISON, Wis., March 1, 2017 /PRNewswire/ -- A study from Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic released today by the American Association of Cancer Research (AACR) shows promise for the development of a blood-based lung cancer test. Researchers conducted a multi-round study of nearly 400 patients, which demonstrated high accuracy for detecting lung cancer at all stages.

Read More

Highlighting our Mission in March

Exact Sciences’ first mission is to help eradicate colon cancer. That mission is on the minds of our team members every single day, and March gives us an opportunity to be even louder about the work we do. Right now, our team members are preparing to take part in some big events to help spread awareness about the nation’s second deadliest cancer and the need for screening.

 
Read More

Exact Sciences generated $99.4 million in revenues during 2016, a 152-percent increase

 

Cologuard gross margin reached 61 percent in fourth quarter

MADISON, Wis., Feb. 21, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $99.4 million and completed approximately 244,000 Cologuard tests during the year ended Dec. 31, 2016. Full-year 2016 revenues and Cologuard test volume grew 152 percent and 135 percent from 2015, respectively.

Read More

CMS Proposes Inclusion of Cologuard in Medicare Advantage Star Ratings

 

Cologuard offers health plans an opportunity to increase screening & improve quality ratings

MADISON, Wis., Feb. 2, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is included in the Medicare Advantage Advance Notice and Draft Call letter.  Cologuard's inclusion in the final Star Ratings will allow Medicare Advantage plans to increase their Star Rating when patients complete Exact Sciences' non-invasive colon cancer screening test.

Read More

More Than Just Numbers

January is a time to reflect on the past year, and the year ahead. This week, I’ll be doing just that when I present at the 35th Annual J.P. Morgan Healthcare Conference. I’ll be reflecting on some big news: In 2016, Exact Sciences completed 244,000 Cologuard tests.

Read More

Exact Sciences to report $99 million in revenues, 150 percent growth for 2016

- Preliminary revenues between $99.0 million and $99.5 million for 2016, a year-over-year increase of 150 percent;
- 244,000 Cologuard tests completed in 2016, a year-over-year increase of 134 percent;
- 9,500 additional providers ordered Cologuard during the fourth quarter, and insurance coverage expanded by 67 percent during 2016. 

MADISON, Wis., Jan. 8, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that the company expects to report revenues between $34.9 million and $35.4 million for the fourth quarter ended Dec. 31, 2016, an increase of 142 percent from the same quarter of 2015. The company completed approximately 82,000 Cologuard tests during the fourth quarter of 2016, which represents growth of 114 percent from the same period of 2015. 

Read More

Cologuard Earns Positive Review from Blue Cross Blue Shield Association

MADISON, Wis., Jan. 5, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Blue Cross Blue Shield Association's (BCBSA) Center for Clinical Effectiveness "Evidence Street" recently released a positive review of Cologuard to its members.  BCBSA is a national federation of 36 Blue Cross and Blue Shield companies that insure one in three Americans. This continues the positive momentum for Cologuard, as coverage increased by 67 percent in 2016 and nearly 163 million Americans are now in health plans that cover the non-invasive colorectal cancer screening option.

Read More